None listed
Conditions
Brief summary
This clinical study aimed to evaluate the effect of adding Coenzyme Q10 as an adjuvant supplement to standard clarithromycin-based triple therapy in patients infected with Helicobacter pylori. The study was conducted at the Modern European Hospital in Sana’a, Yemen, between March and August 2024. A total of 111 adult patients with confirmed H. pylori infection were randomly assigned to receive either standard triple therapy alone or triple therapy plus Coenzyme Q10. The main goal was to assess whether adding Coenzyme Q10 could improve the eradication rate of H. pylori infection and enhance treatment response. Results from this study are expected to contribute to optimizing H. pylori treatment and overcoming antibiotic resistance.
Interventions
Intervention Group: Standard Triple Therapy + Coenzyme Q-10: Participants received standard triple therapy for Helicobacter pylori infection, including film-coated clarithromycin tablets (500 mg) taken orally twice daily for 14 days, amoxicillin tablets (1000 mg) taken orally twice daily for 14 days, and esomeprazole tablets (20 mg) taken orally twice daily for 14 days, plus one capsule (200 mg) of Coenzyme Q-10 dietary supplement once daily for six weeks.
Strategy used to monitor adherence to
Intervention Group: Standard Triple Therapy + Coenzyme Q-10: Participants received standard triple therapy for Helicobacter pylori infection, including film-coated clarithromycin tablets (500 mg) taken orally twice daily for 14 days, amoxicillin tablets (1000 mg) taken orally twice daily for 14 days, and esomeprazole tablets (20 mg) taken orally twice daily for 14 days, plus one capsule (200 mg) of Coenzyme Q-10 dietary supplement once daily for six weeks. Strategy used to monitor adherence to intervention was drug tablet return
Sponsors
Dr Hind Al-Sanabani - University of Science & Technology, Yemen
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 to 65 years with Helicobacter pylori infection diagnosed by a positive stool antigen test and acute dyspeptic symptoms for at least one month. 2. Both males and females. 3. Newly diagnosed cases (no previous treatment for H. pylori).
Exclusion criteria
1. Patients who had received any proton pump inhibitors (PPIs), antibiotics, CoQ10 supplements, H2 blockers, corticosteroids/immunosuppressive, or anti-inflammatory therapy in the previous two months. 2. Patients currently receiving anticoagulant medications (e.g., warfarin), antiplatelet drugs, or statins. 3. Known hypersensitivity to PPIs or antibiotics. 4.Pregnancy or breastfeeding. 5.History of malignancies, previous gastrointestinal surgery, or gastrectomy. 6.Patients suffering from cardiovascular diseases, diabetes, liver disease, or kidney failure.
Outcome results
None listed